chasewnelson on Nostr: One of #Merck’s reasons for suing is likely its cancer drug Keytruda, upon which it ...
One of #Merck’s reasons for suing is likely its cancer drug Keytruda, upon which it relies to maintain yearly profits of US$14.5 billion.
Among other complaints, Merck’s lawyers suggest the company’s ‘free-speech rights’ will be violated. 11/12
Published at
2023-06-15 04:20:46Event JSON
{
"id": "089d8c5b226c8dd0508e0cb2afb1c801787ef1b51f050d6862fa816bd57d2e8f",
"pubkey": "4f8f5b238f242789eaeb4e4198fa7e73358ecafb71a18737b22237aff9e684c5",
"created_at": 1686802846,
"kind": 1,
"tags": [
[
"e",
"b47bb9332f1a047fd45fdc045b7807aa170ea26897667467c157625c86de979c"
],
[
"e",
"61b53ed604fd3bc1359b557b326a2eccb2da22209310509f7703002a66607320"
],
[
"t",
"merck"
]
],
"content": "One of #Merck’s reasons for suing is likely its cancer drug Keytruda, upon which it relies to maintain yearly profits of US$14.5 billion.\n\nAmong other complaints, Merck’s lawyers suggest the company’s ‘free-speech rights’ will be violated. 11/12",
"sig": "2e5b67aa92050d7d67bcad124c408f502e41534fc99c16cf24db79bef2654b33acd99e208c674516a95ca0203c5838bdae52ee429133a727b79328e08dae0c80"
}
